Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers - Wikidata - wikimedia - TriplyDB

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

http://www.wikidata.org/entity/Q24646379

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Current challenges and novel treatment strategies in double hit lymphomas Next-generation prognostic assessment for diffuse large B-cell lymphoma Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma Treatment of diffuse large B cell lymphoma Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Nanotechnology in cancer therapy Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update The Comparative Diagnostic Features of Canine and Human Lymphoma.Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.Progress in central nervous system lymphomas.Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy A prospective study of mediastinal gray-zone lymphoma.A novel role for IL-22R1 as a driver of inflammation.Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma.Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

P2860

Q24597424-FE827B58-1D57-4336-8803-A65AABDD2FDF Q24643447-0E5F6100-E611-4BB8-B802-9EDB2CC0506A Q26770385-CB912C53-8D6E-49CE-83A5-9D23CC48D999 Q26796428-B7E02CB6-681F-42BF-BED7-5B1944937B99 Q26853170-B16CD7D8-3385-4ACE-A088-5287FEB511CF Q27006062-6D0A5959-9D31-4C54-BF96-7AEBB59B6898 Q27016561-238576A7-CAE5-401F-9186-BE4B587B7CD1 Q27023013-4B57146F-685B-4B6D-AF0A-81944178AE82 Q27304386-E0D07F63-22FD-4B35-9DE6-026937CBF844 Q28078869-4BC82F79-FE79-441C-9E58-22710356E1AF Q30401307-9F753CC4-D9C2-41DE-9C1C-D47D24F1C14F Q33399543-4261B3A9-DEA1-41F8-8DEB-2F6C96E977C9 Q33423740-3E34865B-13D0-4805-B585-A6F99425E3B7 Q33561185-80650973-D417-44F1-BA6E-9A668AA25603 Q33805988-F87024E3-4B8C-4A9A-8CE1-5A781E5E368A Q33806007-83983D8E-7940-4BE1-8BB6-E90F4203AE22 Q33828585-55038982-84BB-4F76-905C-D63A82F033AE Q33832087-B3580147-3A70-402F-A57B-DCC5B5C2255B Q33934406-C6E11773-C473-4859-BB35-7F8691953D43 Q34028427-D4C9F762-0C55-4662-A548-3B60EAC7CED3 Q34136990-21839D06-1076-4894-843E-AC1C0FEF8276 Q34542109-C6F5291D-F0AB-48D1-B314-CB1BD94A8A25 Q34617849-956A39D1-E2E9-498C-98DF-7E97C00C36F1 Q34679166-08699D71-1A8F-4A5E-A34A-F613DFF980A8 Q34802443-C70E8431-6D73-43C4-9849-FB230F2A9735 Q35056539-56E50A3A-6927-4CD1-ACBC-45AD04C20EE9 Q35143471-BF4505CE-5896-45C5-9280-0DC5CF2A3DD7 Q35483564-A75EA945-D5D5-4C77-BA7E-B9FFE94CABEE Q35590607-07B760C7-5E83-49F4-B79D-2F561C3BB7D7 Q35700203-80324749-8649-4DE1-A670-C615430B0AE2 Q35783021-5FD5DCBC-441A-4C0B-9EDA-75DC0FA458BA Q35930640-F43B2854-DE16-429B-91A3-AD778AF120F0 Q35989980-784682BE-1D4F-4FFA-A7FA-967E1609AF81 Q36057764-69CAE177-1A25-4F48-BA87-387DBACD216B Q36071772-CA83EF36-98BB-4452-91BA-6BF1F72CA590 Q36192439-47ED9F8D-619F-43FB-AB47-C55D7B5E7D6A Q36515482-802267F9-AA1F-435E-BE82-EB7D4ED39A36 Q36529482-752348A2-6B78-42C3-A017-086AD182569C Q36686045-36EC4982-5457-4CB9-A635-A2D392C61B04 Q36836092-99CDE7A8-6BF9-4889-B680-9FF57A6429A9

P2860

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

http://www.wikidata.org/entity/Q24646379

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@ast

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@en

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@nl

type

label

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@ast

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@en

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@nl

prefLabel

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@ast

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@en

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@nl

P1433

Q24646379-9D0B9632-0839-4791-87FA-D1A4193F848B

P1476

Q24646379-B5F04841-5B23-46B3-AD70-4899A09973CD

P2093

Q24646379-02FDF02B-45E1-4B43-81FF-976A562CEA71

Q24646379-1305F9A6-6938-4C8B-A0D4-962B66206492

Q24646379-4BEDC7EF-8229-41E6-8AF7-682B3F4D3972

Q24646379-5B95C9F6-E122-4A47-9674-0596A6805E19

Q24646379-64146DB4-DD3A-4198-883A-9B3649AAB507

Q24646379-7CAC1AD3-36ED-451E-BA57-47674163B6F9

Q24646379-A42FECFA-21A3-43B9-AFC6-E952C2545BFC

Q24646379-B27F7A3B-9C2E-4E32-9D4F-062D9BF7EF0F

Q24646379-C3637AEA-CBE1-4754-8F23-DFA64C35E714

Q24646379-CED28277-A25D-4C0F-B0EA-BEABEF930B3F

P2860

Q24646379-0D3D5EFF-B5E0-4D5D-89BC-34E37EEC53A0

Q24646379-1B08432F-5DD7-4503-80C9-038B0FA48FFD

Q24646379-223C81AD-7B5C-4BE1-9D57-6FC0890D0AD8

Q24646379-24555BBB-4FD0-46A4-8C19-4A5B1DA36357

Q24646379-2F6920FC-E996-4813-A51B-490856B0E070

Q24646379-316C6326-B03D-4063-ACAD-945D51B13078

Q24646379-490DE478-AF12-4491-8E00-853E9F313F6E

Q24646379-4B896C0D-F400-41D6-9073-2632FF5A4211

Q24646379-4C0D4AF4-9D4D-4CB7-9B88-595A9AAF7FF3

Q24646379-54662B30-25EA-4B9E-8AC5-16119B54E3BB

P304

Q24646379-5E7A323E-962A-49C6-8CCF-80785C58D852

P31

Q24646379-EBA1CE09-043D-4B51-9112-1529E0DAABBC

P3181

Q24646379-C5575436-B467-4393-AB45-918E67666A05

P356

Q24646379-F4A4237C-637B-4855-83C9-1F0D2B49FC11

P407

Q24646379-5A14F211-CAF1-4693-AA94-DE8C7A0496CB

P433

Q24646379-4F293F3F-DDDB-4E98-B716-4A20F7C3D075

P478

Q24646379-CCF863AC-05F6-4C7A-A14F-D26539D57B16

P50

Q24646379-D1FE0031-6083-4673-B588-7CDBD08D7D24

P577

Q24646379-A05C5CA7-01A2-4D41-8C51-F0FC26094D79

P698

Q24646379-611070D4-E53F-48CA-B522-40EEF39FC152

P921

Q24646379-524294F3-7A34-4959-A17D-CC42187870FE

P932

Q24646379-3D9682B8-9FC9-4401-94EB-10BB922CBA85

P3181

P356

JCO.2007.13.1391

P1433

Journal of Clinical Oncology

P1476

Phase II study of dose-adjuste ...... ost-germinal center biomarkers

@en

P2093

Bruce A Chabner

http://www.w3.org/2001/XMLSchema#string

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

John E Janik

http://www.w3.org/2001/XMLSchema#string

Kieron Dunleavy

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Nicole Grant

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Stefania Pittaluga

http://www.w3.org/2001/XMLSchema#string

Upendra Hegde

http://www.w3.org/2001/XMLSchema#string

P2860

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

P304

2717-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4196142

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2007.13.1391

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18378569

http://www.w3.org/2001/XMLSchema#string

P921

P932

2409217

http://www.w3.org/2001/XMLSchema#string